Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains

US6221578A · kind A · utility

Assignee

• Virco N.V. · BE

Inventors

• Marie-Pierre De Bethune · Everberg, BE
• Kurt Hertogs · Antwerpen, BE
• Rudi Pauwels · Champéry, CH

Key dates

• Filing date: Jul 24, 1998
• Grant date: Apr 24, 2001
• Expiry date: Jul 24, 2018

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A90/10
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention is drawn to A method of managing HIV chemotherapy of patients who are HIV positive, which comprises transfecting a cell line susceptible to infection by HIV with a sequence from the pol gene of HIV, which sequence encodes a desired target enzyme, obtained by isolating viral RNA from a sample of a biological material from a patient and reverse transcribing the desired region of the pol gene, and a HIV-DNA construct from which the sequence has been deleted, culturing the transfected cells so as to create a stock of chimeric viruses providing an indication of the resistance profile of the circulating virus, assessing the phenotypic sensitivity of the chimeric viruses to an inhibitor of the enzyme encoded by the pol gene of HIV and assigning a value thereto, constructing a data set comprising the value for chimeric virus sensitivity and the corresponding value for a chimeric wild-type strain of HIV, repeating the sensitivity assessment for at least two further inhibitors and thereby constructing at least three such data sets in total, representing the data sets in two dimensional or three dimensional graphical form such that the difference between the chimeric and…